deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03534323

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma or Patients With Richter's Syndrome

Sponsor: Dana-Farber Cancer Institute

Conditions Chronic Lymphocytic Leukemia Richter Syndrome
Interventions Duvelisib Venetoclax
Updated 17 times since 2018 Last updated: Aug 12, 2025 Started: Jul 12, 2018 Primary completion: Dec 1, 2024 Completion: Jul 1, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03534323, this PHASE1/PHASE2 trial focuses on Chronic Lymphocytic Leukemia and Richter Syndrome and remains ongoing. Sponsored by Dana-Farber Cancer Institute, it has been updated 17 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Aug 2019 · 12 months · monthly snapshot~Aug 2019 – ~Dec 2019 · 4 months · monthly snapshot~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Oct 2021 · 4 months · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Sep 2022 · 9 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Sep 2023 · 7 months · monthly snapshot~Sep 2023 – ~Feb 2024 · 5 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Feb 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Sep 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  4. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 12 earlier versions

  1. Feb 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  2. Sep 2023 — Feb 2024 [monthly]

    Recruiting PHASE1_PHASE2

  3. Feb 2023 — Sep 2023 [monthly]

    Recruiting PHASE1_PHASE2

  4. Sep 2022 — Feb 2023 [monthly]

    Recruiting PHASE1_PHASE2

  5. Dec 2021 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  6. Oct 2021 — Dec 2021 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jun 2021 — Oct 2021 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE1_PHASE2

  9. Dec 2019 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  10. Aug 2019 — Dec 2019 [monthly]

    Recruiting PHASE1_PHASE2

  11. Aug 2018 — Aug 2019 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  12. Jun 2018 — Aug 2018 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dana-Farber Cancer Institute
  • Secura Bio, Inc.
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations